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Fortified interpenetrating polymers – bacteria
resistant coatings for medical devices†
Seshasailam Venkateswaran,‡a Orlando David Henrique Dos Santos,‡b
Emma Scholefield,c Annamaria Lilienkampf,a Peter J. Gwynne,d David G. Swann,e
Kevin Dhaliwal,c Maurice P. Gallagher*d and Mark Bradley*a
Infections arising from contaminated medical devices are a serious global issue, contributing to antibiotic
resistance and imposing significant strain on healthcare systems. Since the majority of medical device-
associated infections are biofilm related, efforts are being made to generate either bacteria-repellent or
antibacterial coatings aimed at preventing bacterial colonisation. Here, we utilise a nanocapsule mediated
slow release of a natural antimicrobial to improve the performance of a bacteria repellent polymer coating.
Poly(lauryl acrylate) nanocapsules containing eugenol (4-allyl-2-methoxyphenol) were prepared and
entrapped within a interpenetrating network designed to repel bacteria. When coated on a catheter and an
endotracheal tube, this hemocompatible system allowed slow-release of eugenol, resulting in notable
reduction in surface-bound Klebsiella pneumoniae and methicillin resistant Staphylococcus aureus.
Introduction
Polyurethanes, polysilicones and polyvinyl chloride are widely
used in the manufacture of medical devices due to their
biocompatibility and good mechanical properties.1 However,
microorganisms can adhere to these polymeric surfaces, result-
ing in medical devices being one of the most common sources
of nosocomial infections.2 Once bacteria attach to the surface,
they multiply and subsequently form a biofilm (matrix composed
of exopolysacharides, proteins, teichoic acids and extracellular
DNA), which is a source of a chronic infection.3–5 Bacterial
biofilms are inherently resistant to antimicrobials5 and, aided
by the protection of biofilms and limited diffusion,4 bacteria
may be exposed to sub-inhibitory concentrations of antibiotics
during treatments, promoting the development of antibiotic
resistance. Therefore in an effort to reduce biofilm formation,
coatings have been developed for medical devices that will either
inhibit attachment of bacteria or kill bacteria on contact.1
Coatings to reduce bacterial binding include hydrophilic polymers
such as poly(ethylene glycol) (PEG),6 peptide–PEG amphiphilic
macromolecules,7 pluronic surfactants,8 zwitterionic poly-
urethanes,9 and super hydrophobic coatings.10 Previously, we
have reported the high-throughput identification of bacteria
repelling polymers,11,12 with poly(methyl methacrylate-co-dimethyl-
acrylamide) (PA13) in particular demonstrating reduced binding of
several clinical isolates on coated medical devices.12 Coatings that
inherently reduce bacterial attachment are an attractive strategy;
however, in situ formation of layers of bacterial and host compo-
nents on the device surface promotes bacterial attachment
reducing their effectiveness.1 Hence, a bacteria repellent coating
that also incorporates antibacterial components that inhibit
biofilm formation offer the potential to be more effective.13
Clove oil and its major ingredient eugenol (4-allyl-2-methoxy-
phenol) have been studied as broad-spectrum antimicrobials
with various mechanisms of action proposed.14–16 FDA approved
eugenol (used in dentistry as an analgesic) has been reported
to inhibit formation of biofilms of Klebsiella pneumoniae
(K. pneumoniae),17 Staphylococcus aureus (S. aureus)18 and Candida
albicans19 at sub-inhibitory concentrations without promoting resis-
tance due to its multi-target mode of action.20 Reduced expression
of virulence-related exoproteins21 and down-regulation of biofilm-
associated genes22 by eugenol have also been demonstrated. At sub-
inhibitory concentrations, eugenol interacts synergistically with
various antibiotics (e.g. penicillin, ampicillin, oxacillin, erythromycin
and polymyxin B) to reduce their minimum inhibitory concen-
tration against K. pneumoniae (up to 1000-fold reduction).23
The most common coatings for catheters to inhibit bacterial
attachment are based on a combination of chlorhexidine and
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silver sulfadiazine, with chlorhexidine associated with anaphy-
lactic shocks.24,25 Organisms such as Acinetobacter baumannii
exhibit resistance to Chlorhexidine via overexpression of a
chlorhexidine efflux protein.26 Moreover, discovery of resis-
tance to silver,27 including complete resistance to nine different
commercially available silver-based wound dressings, in
Klebsiella pneumoniae and Enterobacter cloacae highlights the
need for new coating strategies.
Here, eugenol was investigated as antibacterial agent for
bacterial repellent coating. However, like chlorhexidine28 and
silver sulfadiazine,29 eugenol is known to be toxic to mammalian
cells30 at high concentrations (B4% hemolysis at 2 mg mL1).19
Therefore, a coating consisting of a bacteria repellent polymer
PA13 with the slow-release of eugenol was envisaged. Poly(lauryl
acrylate)-based nanocapsules encapsulating clove oil or eugenol
were prepared and evaluated for their ability to inhibit growth of
two of the most common hospital pathogens, methicillin resis-
tant S. aureus (MRSA) and K. pneumoniae, on polymer surfaces
(Table 1). A strategy to incorporate the nanocapsules into PA13
with slow-release of eugenol was investigated, resulting in the
development of a ‘fortified interpenetrating polymer network’
with eugenol nanocapsules entrapped within a Porous-PA13 (first
network) and a poly(ethylene glycol) diacrylate (second network)
(Fig. 1). This polymer network was applied to two medical devices
(a catheter and an endotracheal tube) with a luminescence based
microbial viability assay and scanning electron microscopy (SEM)
used to study binding of bacteria.
Materials and methods
Kolliphors RH40 was obtained from BASF, HPLC grade water
was from Fisher Scientific, eugenol (Z98%, natural) and all
other chemicals were from Sigma. MRSA (ATCC 252) and
K. pneumoniae (ATCC BAA1706) were purchased from the
American Type Culture Collection. The UV light source used
for all polymerisation experiments was a UVP (model CL-1000,
365 nm, 8 Watt, 1000 mJ cm2). The UV light of the culture
hood was used for sterilisation. PA13 and PA155 were synthe-
sised as described previously.12
Preparation of nanocapsules
Nanocapsules were prepared by the phase inversion temperature
method, as described previously31 with somemodifications (Fig. 2).
Nanoemulsions (5 mL scale) were prepared either as blank
(no antibacterials), or with 5% of clove oil or eugenol. 0%, 1%, or
2% of crosslinker 1,6-hexanediol diacrylate, 10% lauryl acrylate,
surfactants (7.5% Kolliphors RH40 and 2.5% Spans 80) and
eugenol (or clove oil) were heated to 80 1C in a glass vial and
Table 1 Polymers and polymer networks used in this study (Fig. 1) (PDI =
polydispersity index). For chemical structures see ESI Section 16
Polymer Description
PA13 Co-polymer of methyl methacrylate and dimethylacrylamide
(polymerised in amolar ratio of 9 : 1,Mw 411 kDa, PDI 3.4).
12
Bacteria repelling polymer surface.
PA155 Co-polymer of hydroxyethyl methacrylate and dimethyl-
aminoethyl methacrylate (polymerised in a molar ratio
of 1 : 1, Mw 9.45 kDa, PDI 1.2).
12 This bacteria-binding
polymer11 was used as a control surface.
Crosslinked-
PA13
PA13 crosslinked with 4.1 mol% poly(ethylene glycol)
diacrylate (PEGDA-575).
Porous-PA13 Crosslinked-PA13 prepared with 3 kDa poly(ethylene
glycol) as a porogen (B17% w/w).
Eugenol-
Network
Fortified interpenetrating polymer network prepared
with Porous-PA13 as the first network and PEGDA-575
as the second network with eugenol nanocapsules
entrapped in the polymer network.
Blank-
Network
An interpenetrating network prepared with Porous-PA13
as the first network and PEGDA-575 as the second
network with no nanocapsules.
Fig. 1 (A) Polymers based on methyl methacrylate and dimethylacryl-
amide (9 : 1 molar ratio) used in this study. PA13 was prepared by free radial
polymerisation using azobisisobutyronitrile (AIBN).12 Crosslinked-PA13 was
prepared by photopolymerisation of PA13 monomers and 4.1%
poly(ethylene glycol) diacrylate (PEGDA-575) as crosslinker. Porous-PA13
was prepared as above but with poly(ethylene glycol) (PEG-3000) included
as a porogen. (B) Preparation of the fortified interpenetrating network.
Porous-PA13 (first network) was incubated with eugenol containing
poly(lauryl acrylate) nanocapsules followed by the entrapment of the
nanocapsules by the second network composed of PEGDA-575.
Fig. 2 Synthesis of nanocapsules by phase inversion temperature method.
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mixed vigorously using a magnetic stirrer until melting and
homogeneous dissolution of all the components. Water (pre-
heated to 80 1C) was added dropwise to the oil phase, the vial
was sealed and the mixture stirred at 80 1C for 10 min to form a
water-in-oil emulsion. The mixture was cooled to room tempera-
ture and mixed overnight to give an oil-in-water nanoemulsion.
Where formulations formed viscous water-in-oil emulsions above
their phase inversion temperature, they were either vortexed or
shaken intermittently during the cooling stage. Irgacures 2959
(1% w/w) was added to the nanoemulsions, mixed until complete
dissolution, and the mixture placed in an ice bath before
polymerisation under UV light for 1 h under continuous mixing.
After irradiation, samples were mixed for 2 h at room tempera-
ture and stored under ambient conditions. Particle size distribu-
tion and polydispersity index was obtained by dynamic light
scattering after each step (emulsification and polymerisation)
using a Zetasizer (Nano-ZS, Malvern Instruments). The samples
were diluted (10% v/v) with HPLC grade water with readings
taken at 22 1C, with a scattering angle of 1731. See ESI,† Section 1
and Table S1 for composition optimisation studies.
Transmission electron microscopy
Transmission Electron Microscopy (TEM) of the nanocapsules
was performed using a Philips/FEI CM120 Biotwin Transmission
Electron Microscope. Samples were diluted in water (5% v/v),
dropped into a TEM grid holder and left to dry at room tempera-
ture overnight inside a desiccator prior to imaging.
Antimicrobial assays
2 Mueller-Hinton broth was inoculated with 2  106 CFU mL1
MRSA or K. pneumoniae and challenged with equal volume of
the nanocapsule dispersions (diluted in PBS to yield eugenol
or clove oil concentrations of 0.625, 0.25, 0.1875, 0.125, and
0.025 mg mL1) for 16 h allowing growth curves and IC50 values
to be determined (ESI,† Section 10). Bacterial viability in
nanocapsule-challenged media was compared with PBS (nega-
tive control) and hydrogen peroxide (8% w/w) (positive control)
using the BacTiter-GloTM (Promega) microbial viability assay
(ESI,† Section 11).
Bacterial attachment on polymer coated coverslips
Glass coverslips (19 mm diameter) were coated with PA13,
PA155 and Crosslinked-PA13 (ESI,† Sections 3 and 4). 400 mL
of undiluted non-crosslinked nanocapsule dispersions were
pipetted on to the coverslips in a 6-well plate and spread over
the surface. After 1 h incubation, the coverslips were washed
with PBS (2  2 mL) and sterilised by UV light for 30 min before
inoculating with bacteria. Luria-Bertani (LB) broth inoculated
with MRSA or K. pneumoniae (2  106 CFU mL1) was pipetted
into the 6-well plates (2 mL per well) and incubated for 24 h
at 37 1C. Media was removed and the coverslips washed with
PBS (2  2 mL). The coverslips were incubated (1 h) with 10%
formalin in PBS containing 1 mg mL1 of Hoechst 33342, and
washed with PBS (2 mL). Coverslips were imaged using the
DAPI channel (lex/em 357/447 nm) of an EVOS FL microscope
with a 60 objective.
Coating of medical devices
A central venous catheter (polyurethane, Arrow international,
CS12123E) was cut into cylindrical pieces of approximately
5 mm in length (weight 41–45 mg) and an endotracheal tube
(polyvinyl chloride, Rusch, 112482) was punched to obtain circular
pieces of 10 mm diameter.
For coating with Porous-PA13, the surface of the catheter
pieces was first roughened with a scalpel. Each piece was held
at the central lumen and dip-coated with the polymerisation
mixture containing the monomers, crosslinker, initiator, solvent
and PEG-3000 (see ESI,† Section 5 for composition), followed by
polymerisation under UV light for 1 h. The dip-coating and
polymerisation was repeated holding the other side of the
catheter piece. For coating the tracheal tube, roughened pieces
were placed into a silicone mould (10 mm diameter, 5 mm
depth) prepared using a silicone elastomer (Mold Star 15 Slow).
150 mL of the polymerisation mixture was pipetted onto the
surface and photopolymerised for 1 h, and the process repeated
on the other side. The catheter and tracheal tube pieces were
washed thoroughly with water and incubated sequentially with
40 mL of water (2  15 min), 50% acetone in water (5 min) and
water (15 min), followed by freezing (dry ice) and lyophilisation.
The dried catheter and tracheal tube pieces coated with Porous-
PA13 were soaked in the non-crosslinked eugenol containing
nanocapsules (100 mL per sample) for 30 min, lyophilised for 2 h,
and dipped into a poly(ethylene glycol) diacrylate (PEGDA, 575 Da)
solution (containing PEGDA, Irgacures 2959, methanol and water
at 10%, 2%, 8% and 80%w/w, respectively) and photopolymerised
for 30 min to give Eugenol-Network coating.
For coating with PA13 (control) the catheter and tracheal
tube pieces were dipped into a 10% solution of PA13 in acetone,
dried for 2 h under ambient conditions, coating repeated on
the other side and the pieces dried overnight.12
Reduction in bacterial binding on fortified interpenetrating
polymer network
To quantify the reduction in bacterial binding by eugenol
encapsulated nanocapsules trapped in an interpenetrating
polymer network, monoliths of Porous-PA13, Eugenol-Network
and Blank-Network were prepared (ESI,† Section 5 and 6) and
quantification of surface-bound bacteria was performed using
the process described previously.32 The monoliths (3  10 mm
cylinders, n = 3) were sterilised under UV light (20 min each
side), washed with water (2  40 mL), and placed in a 24 well-
plate. MRSA and K. pneumoniae in LB broth (2  106 CFU mL1)
were added (2 mL per well) (ESI,† Section 9) and incubated for
24 h at 37 1C. The monoliths were transferred to a clean 24-well
plate, washed with PBS (2  2 mL), transferred to a 24-well plate
containing LB broth (1 mL per well) and the media pipetted
up and down 10 times vigorously to dislodge surface bound
bacteria. Resultant cultures were incubated for 2 h at 37 1C
(wells with 1 mL of media without bacteria used as control).
500 mL from each well was removed and added to 500 mL
of BacTiter-GloTM reagent (prepared as per manufacturer’s
instructions) and mixed thoroughly by pipetting. 100 mL from
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each well was transferred to an opaque 96-well plate and
luminescence was recorded using a Biotek Synergy HT well
plate reader (autogain, shaking 5 min).
The surface-adhered bacteria on uncoated endotracheal tube
and on monoliths of the Eugenol-Network and the Blank-Network
(ESI,† Section 6) were determined by the same method.
Scanning electron microscopy (SEM)
Catheter and endotracheal tube pieces, uncoated and coated
with PA13 or Eugenol-Network, were sterilised with UV light
(20 min each side) and incubated with the bacterial cocktail
described above. After washing with PBS (2  2 mL), surface-
attached bacteria were fixed with 10% formalin (2 mL per well,
1 h), washed with PBS, and dried in a fume hood overnight. The
pieces were coated with a gold/palladium (60/40%) alloy using
an Emscope SC500A sputter coater and SEM images obtained
using a Hitachi 4700 II, cold field-emission Scanning Electron
Microscope.
Results and discussion
Preparation of nanoemulsions and nanocapsules
Poly(lauryl acrylate) nanocapsules31 were prepared by photo-
polymerisation of oil-in-water nanoemulsions composed of an
oil phase containing lauryl acrylate (10% w/w), eugenol or clove
oil (5% w/w) and varying degrees of 1,6-hexanediol diacrylate
(0, 1, 2% w/w) as a crosslinker (Fig. 2, ESI,† Table S1). Lauryl
acrylate was chosen as the hydrophobic monomer due to its
previous success in the efficient production of polymeric nano-
particles.31 Nanoemulsions were prepared by phase inversion
temperature emulsification, which is a low energy technique
utilising the temperature-dependent reduction in interfacial
tension between aqueous and oil phases that is induced by
non-ionic surfactants that incorporate polyethylene oxide.33,34
The reduced interfacial tension allows for better droplet break
up and hence smaller particle sizes.35 Emulsification was con-
ducted at 80 1C and the composition of the surfactants was
optimised (7.5% Kolliphors RH40 and 2.5% Spans 80) to
achieve a stable nanoscale emulsion (ESI,† Section 1).
The nanoemulsion oil droplets containing the monomers and
antimicrobials can be likened to ‘nanoreactors’31 undergoing poly-
merisation to form nanocapsules. TEM images of the nanocapsules
prepared by in situ photopolymerisation of the nanoemulsions
showed differing morphologies for the unloaded and eugenol or
clove oil loaded nanocapsules (Fig. S2, ESI†). All nanocapsules had
a size ofo100 nm with a PDI ofo0.16 (Fig. S3, ESI†).
Antibacterial activity of eugenol and clove oil nanocapsules
Nanocapsules loaded with eugenol or clove oil with varying
degree of crosslinking were assessed for their ability to inhibit
growth of MRSA and K. pneumoniae. Both species were affected
by the antibacterial loaded nanocapsules in a dose dependent
manner (ESI,† Section 10), with 450% inhibition at a concen-
tration of 0.625 mg mL1 of eugenol or clove oil. K. pneumoniae
showed greater susceptibility than MRSA with eugenol loaded
nanocapsules showing B3-fold greater inhibition than clove oil.
IC50 values for eugenol in nanocapsules (after 16 h incubation)
for both bacteria werer0.35 mg mL1, similar to free eugenol.19
The degree of crosslinking of the capsules did not influence
their antibacterial activity. Evaluation of bacterial viability via
BacTiter-GloTM microbial viability assay (ESI,† Section 11) con-
firmed the anti-bacterial activity of the eugenol and clove oil
containing nanocapsules.
To assess the ability of surface-coated nanocapsules to reduce
bacterial binding, PA155 (a polymer that promotes bacterial
binding11) coated coverslips were treated with nanocapsules,
incubated with MRSA and K. pneumoniae for 24 h and the bacteria
were fixed and stained. Analysis by fluorescence imaging after
Hoechst 33342 staining showed a clear reduction of binding of
both species on surfaces with the nanocapsules when compared to
untreated controls (Fig. S11, ESI†). Coverslips coated with bacteria-
repelling polymers PA13 and Crosslinked-PA13 also showed that
addition of surface-coated nanocapsules further reduced bacterial
binding on these polymers (Fig. 3 and Fig. S11, S12, ESI†) with
Fig. 3 Coverslips coated with PA13 showing reduced binding of K. pneumoniae and MRSA for surfaces loaded with clove oil or eugenol containing
nanocapsules (no crosslinker) when compared with blank-treated or untreated controls (scale bar 50 mm). PA13 coated coverslips treated with non-crosslinked
nanocapsules were incubated with bacteria for 24 h, and the bacteria fixed and stained with Hoechst 33342. The coverslips were imaged in the DAPI channel
(lex/em 357/447 nm, 60 objective) and the images processed using ImageJTM, providing an image of black bacteria against a white background.




















































































This journal is©The Royal Society of Chemistry 2016 J. Mater. Chem. B, 2016, 4, 5405--5411 | 5409
eugenol encapsulated nanocapsules producing the best bacteria
repelling surfaces (B78–100% reduction of bacteria binding
observed on PA13, PA155 and Crosslinked-PA13).
Preparation of eugenol releasing fortified interpenetrating
polymer network
Fortified interpenetrating polymer networks, encapsulating the
eugenol-loaded nanocapsules, were prepared (ESI,† Section 6).
This double network structure was required, as PA13 itself
could not be used to trap nanocapsules (PA13 is insoluble in
solvents compatible with the nanocapsules and in situ trapping
during polymerisation was not possible due to incompatibly of
the monomers with the nanocapsules) while Crosslinked-PA13
did not allow nanocapsule penetration (ESI,† Section 8.1).
Firstly, monoliths of Porous-PA13 were prepared by photo-
polymerisation of monomers (methyl methacrylate and dimethyl-
acrylamide in a 9 : 1molar ratio) with the crosslinker poly(ethylene
glycol) diacrylate (4.1 mol% of PEGDA-575) in MeOH36 with
polyethylene glycol (3 kDa) as a porogen (ESI,† Section 5), which
allowed incorporation of the nanocapsules into the polymer
(Fig. 4, ESI,† Section 8.2).
For the preparation of the fortified interpenetrating polymer
network, Porous-PA13 was incubated with non-crosslinked eugenol
containing nanocapsules, which were subsequently trapped into
the coating by introduction of a second polymer network prepared
from poly(ethylene glycol) diacrylate (PEGDA-575) (ESI,† Section 6).
This second network eliminates leaching of the nanocapsules
(monoliths of Porous-PA13 without second network showed
60% nanocapsule release after 20 h incubation in water. See
ESI,† Table S2). The Eugenol-Network had a nanocapsule content
of 42  3 mg mm3 (calculated based on eugenol content per
monolith, see ESI,† Section 7).
Quantification of eugenol release from the Eugenol-Network
via HPLC analysis showed a slow and controlled release with
less than 10% of eugenol released after 24 h (15% after 72 h)
(Fig. 5), suggesting that the coating can retain its anti-fouling
nature for an extended duration. This is vital as catheters can
remain in use for long periods, while burst release can lead
to toxicity.
Fortified interpenetrating polymer network reduces bacterial
attachment and is biocompatible
This Eugenol-Network coating (prepared as a monolith) was
assessed for its ability to inhibit binding of MRSA and
K. pneumoniae. After overnight incubation with a cocktail of
K. pneumoniae and MRSA, an ATP luminescence assay was used
to quantify the level of surface-bound bacteria. The eugenol
containing monoliths showed up to 90% reduction in lumines-
cence compared to controls (Porous-PA13 and Blank-Network)
(Fig. 6A), confirming the ability of the nanocapsules to reduce
bacterial viability. Bacterial binding was also compared with
the Eugenol-Network and a surface of a polyvinyl chloride
endotracheal tube with the Eugenol-Network monoliths showing
86% fewer bacteria than the endotracheal tubes (Fig. 6B).
No hemolysis was observed after 1 h incubation of Eugenol-
Network monoliths with human erythrocytes (ESI,† Section 14),
confirming the biocompatibility of the coatings.
Bacterial binding on the surface of coated catheters and
endotracheal tubes
Twomedical devices, a polyvinyl chloride based endotracheal tube
and a polyurethane based central venous catheter, were coated
Fig. 4 SEM images of sliced sections of Porous-PA13 monoliths incubated with blank nanocapsules with 0–2% crosslinker showed penetration of the
nanocapsules (arrows) into the polymer network. Scale bar top row 10 mm (2000) and bottom row 2 mm (3500).
Fig. 5 The time-dependent release of eugenol from the polymer coating.
Monoliths of Eugenol-Network were incubated with 1 mL of water at room
temperature and analysed by HPLC. 100% release was quantified by
soaking the monoliths in 2 mL of methanol overnight followed by crushing
and sonication and HPLC analysis.
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with Porous-PA13, followed by incubation with eugenol con-
taining nanocapsules, which were trapped by a second network.
After incubation with a cocktail of K. pneumoniae and MRSA,
surface bound bacteria were examined via SEM. The SEM images
showed patches of bacterial colonisation on the uncoated medical
devices, with no colonisation observed on the Eugenol-Network
coating (Fig. 7). The observed reduction in bacterial binding,
together with the biocompability and slow release of eugenol,
clearly demonstrate the potential of these polymers for clinical
applications.
Conclusions
Poly(lauryl acrylate) based nanocapsules encapsulating eugenol
were synthesised by the phase inversion temperature method
and shown to inhibit growth and reduce binding of two major
pathogens, Gram-negative K. pneumoniae and Gram-positive
MRSA, demonstrating their potential for use in antibacterial
coatings. The eugenol containing nanocapsules were success-
fully trapped within a porous polymer coating to give a ‘fortified
interpenetrating polymer network’, which allowed slow release
of eugenol without hemolytic activity. When applied as a coating
on two medical devices this Eugenol-Network showed significant
reduction in binding of bacteria showing the value of the coating
as a means of combating medical-device associated infections.
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MRSA (scale bar 10 mm). The arrows show surface attached bacteria.
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